BSD-2000 PMA
This article was originally published in The Gray Sheet
Executive Summary
BSD Medical submits premarket approval application for tumor hyperthermia therapy May 22. The PMA is based on data from approximately 4,000 treatments of more than 800 patients (1"The Gray Sheet" Jan. 19, 2006, p. 15). The device employs an array of radiofrequency antennae to generate enough energy to target and kill cancer cells...
You may also be interested in...
Heat therapy for cancer
High-risk soft tissue sarcoma patients treated with BSD Medical's BSD-2000 hyperthermia system in addition to chemotherapy had nearly double the median time of disease free-survival (31.7 months) and local progression-free survival (45.3 months) compared with those only receiving chemotherapy, according to study results presented June 4 at the American Society of Clinical Oncology conference in Chicago. The 340-patient randomized trial was based on the belief that precision-focused, mild heating of cancer improves blood flow and leads to better absorption of chemotherapy drugs, in addition to directly killing cancer cells and improving chemical reactions of some drugs. BSD Medical submitted a PMA application for the BSD-2000 in May 2006 (1"The Gray Sheet" May 29, 2006, In Brief)...
BSD Medical Plans To File PMA For Cancer Therapy, Prepares Japanese Strategy
BSD Medical plans to submit a PMA application by the end of the quarter for its non-invasive BSD-2000 tumor hyperthermia therapy system to treat cancer
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.